Related Experiment Video
Updated: May 11, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Pharmacoresistant epilepsy: unmet needs in solving the puzzle(s)
Donald F Weaver1, Bernd Pohlmann-Eden
1Department of Medicine Neurology, Dalhousie University, Halifax, Nova Scotia, Canada. donald.weaver@dal.ca
Epilepsia
|May 8, 2013
Summary
Pharmacoresistant epilepsy poses a significant challenge. Addressing key research needs, from defining the condition to developing new treatments, is crucial for improving patient lives.
Area of Science:
- Neurology
- Epileptology
- Clinical Research
Background:
- Pharmacoresistant epilepsy affects a significant patient population.
- Current understanding and treatment strategies for pharmacoresistant epilepsy are limited.
- The 2nd Halifax International Epilepsy Conference & Retreat highlighted critical unmet needs.
Purpose of the Study:
- To identify and outline crucial research priorities for pharmacoresistant epilepsy.
- To guide future research efforts toward improving outcomes for individuals with refractory epilepsy.
- To foster advancements in the definition, understanding, and treatment of pharmacoresistant epilepsy.
Main Methods:
- Consensus identification of research needs by experts at the 2nd Halifax International Epilepsy Conference & Retreat.
- Systematic review and synthesis of current knowledge gaps in pharmacoresistant epilepsy.
- Expert-driven formulation of a research agenda.
Main Results:
- Ten key areas of need were identified, including.
- Development of an evidence-based definition for pharmacoresistant epilepsy.
- Comprehensive understanding of natural history, complications, and comorbidities.
- Epidemiological and socioeconomic impact assessment.
- Identification of physiologically and anatomically based biomarkers (EEG and MRI).
- Elucidation of biomolecular mechanisms and etiopathogenesis.
- Development of representative animal models.
- Discovery of novel therapeutic strategies and drugs.
- Promotion of research and funding for pharmacoresistant epilepsy.
Conclusions:
- Addressing the identified research needs is paramount for advancing the care of patients with pharmacoresistant epilepsy.
- A multi-faceted research approach is required, encompassing basic science, translational research, and clinical studies.
- Prioritizing these research areas will facilitate the development of more effective treatments and improved quality of life for individuals living with refractory epilepsy.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...